Objective: Hypogonadism is a major complication in testicular cancer survivors, but its prevalence varies among studies. In Japan, free testosterone has been used for diagnosis of late-onset hypogonadism syndrome. In the present study, we evaluated the hormone level of testicular cancer survivors and its impact on their quality of life. Methods: Overall, 50 testicular cancer survivors treated from 1990 to 2013 were enrolled. The median age was 44 years. The serum levels of free testosterone, total testosterone and luteinizing hormone were measured. All patients completed the Aging Males' Symptom scale and International Index of Erectile Function-15. The hormone levels of 337 healthy volunteers were used as the control. Results: A total of 32 (64%) patients showed free testosterone levels <8.5 pg/mL. In contrast, just 26% of 50 patients showed total testosterone levels <3.5 ng/mL. Testicular cancer survivors had significantly lower free testosterone and higher luteinizing hormone compared with healthy controls. In contrast, there was no difference in total testosterone between patients and controls. The prevalence of late-onset hypogonadism symptoms of any grade (Aging Males' Symptom total score ≥27) was 60%. Overall, 64% were defined as having moderate erectile dysfunction (International Index of Erectile Function-Erectile Function domain score <17). However, Aging Males' Symptom, International Index of Erectile Function-15 and Erectile Function domain scores did not differ by free testosterone or total testosterone level. Conclusions: This is the first report on the prevalence of hypogonadism determined by free testosterone level in Japanese testicular cancer survivors. Because Aging Males' Symptom and International Index of Erectile Function-15 scores do not necessarily reflect the hormone level, measuring free testosterone is also important in the follow up of these patients.
Introduction
Secondary malignant neoplasms, cardiovascular disease, neuropathy, nephrotoxicity and hypogonadism are important long-term complications among TC survivors. The first two are potentially fatal morbidities.
1,2 Whereas hypogonadism is not fatal, it can adversely affect the QoL through symptoms known as LOH syndrome or ED. [3] [4] [5] [6] Furthermore, several populationbased studies or meta-analyses showed that a low serum testosterone level is a significant risk factor for developing cardiovascular disease. 7 Multiple factors are known to be responsible for the development of hypogonadism in TC survivors, and these include pre-existing testicular dysgenesis, orchiectomy and chemotherapy-induced gonadal dysfunction. However, some studies showed a higher risk of hypogonadism in survivors treated with chemotherapy compared with those treated with orchiectomy alone, 3, 4 whereas others showed no difference between the two patient groups. 5 On this point, a recently published meta-analysis showed that survivors treated with chemotherapy have a significantly higher risk for developing hypogonadism compared with survivors treated with orchiectomy alone.
The prevalence and severity of hypogonadism in chemotherapy-treated TC are varied among studies. [3] [4] [5] This might be partly due to differences in chemotherapy intensity and observation period. In addition, there are several limitations to previous studies. First, most of the studies did not use healthy age-matched controls. Because testosterone levels decrease with aging, an age-matched reference is preferred. Second, limited data is available about the effects of hypogonadism on patients' QoL. Third, most studies used total T rather than free T. To our knowledge, there were just four published studies that evaluated free T among TC survivors treated with chemotherapy. 5, [9] [10] [11] Those studies showed no specific free T threshold for the diagnosis and management of LOH symptoms. This is inconvenient for Japanese researchers, because Japanese clinical practice manuals recommend measuring free T levels for the diagnosis of LOH syndrome. [12] [13] [14] [15] In contrast to Western countries, several studies did not show an age-dependent decrease of total T in Japanese men. [13] [14] [15] Therefore, total T is not a useful marker for hypogonadism.
To overcome these obstacles, in the present study, we evaluated the prevalence of hypogonadism determined by free T levels, and we also evaluated the association between LOH or ED symptoms and hormonal disturbance in TC survivors as a single-institutional prospective study. For assessment of QoL, both the AMS scale 16 and IIEF-15 17 were used. In the present study, we showed the prevalence of hypogonadism and several other interesting results.
Methods

Patients and controls
The present study was carried out as a part of a prospective study of investigative research on QoL and long-term complications in TC survivors. The study was approved by the ethics committee of Tsukuba University Hospital (approval number: H24-23). Written informed consent was obtained from each patient. A total of 52 TC patients who had been treated at Tsukuba University Hospital (Tsukuba, Ibaraki, Japan) between 1990 and 2013 were enrolled. Of them, two patients were excluded from the study because they underwent bilateral orchiectomy. Therefore, a total of 50 TC patients were analyzed. In addition to TC survivors, the serum free T, total T and LH levels of 337 healthy volunteer men at St. Marianna University Hospital (Kawasaki, Kanagawa, Japan) were used as healthy controls. The data were obtained from some of the participants in two multicenter studies for evaluation of semen quality between 1999 and 2003. 18, 19 Briefly, 187 of 337 were healthy volunteer university students. 18 Another 150 men were partners of pregnant women who attended the antenatal care clinics located in urban areas close to St. Marianna University. 19 None of them had a history of cryptorchidism, testicular torsion, orchitis, varicocele or inguinal hernia. Written informed consent was obtained from each healthy volunteer. Details about the recruitment process of controls are described in Appendix S1.
Laboratory tests and QoL questionnaires
Blood samples were taken from 08.00 to 11.00 hours at routine TC follow-up outpatient clinic visits. Free T was measured using an analog ligand radioimmunoassay (Diagnostic Products, Los Angeles, CA, USA). Total T was measured using a chemiluminescence immunoassay (Abbott Japan, Chiba, Japan). LH was measured using an enzyme immunoassay (Tosoh, Tokyo, Japan). The reference range of LH is 1.7-11.2 mIU/mL. On the same day, patients were asked to complete AMS scales and IIEF-15. According to AMS scores, patients were considered to have mild (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) or moderate-to-severe (≥37) LOH symptoms, respectively. According to the IIEF-EF domain score, patients were considered to have moderate (12) (13) (14) (15) (16) (17) or severe (<11) ED symptoms, respectively.
Statistical analysis
The v 2 -test and Mann-Whitney U-test were used to compare the characteristics of patients. The risk factors for hypogonadism (free T <8.5 pg/mL) were analyzed with univariate and multivariate logistic regression models. P-values <0.05 are considered to be significant. Statistical analyses were carried out using JMP 11 software (SAS Institute, Cary, NC, USA).
Results
Characteristics of patients and healthy controls
The patient characteristics are summarized in Table 1 . The median age was 44 years. At enrolment in the study, all patients had had a continuous cancer-free status. The median follow-up period from the completion of treatment was 5.8 years. The median BMI was 23.7. The median age of healthy controls was 23 years. The characteristics of healthy controls are summarized in Table 2 .
Treatment for testicular cancer
All patients underwent unilateral orchiectomy. As shown in Table 1 , there were six non-metastatic patients. Of them, four received orchiectomy only, and two received orchiectomy and radiotherapy. The remaining 44 (88%) patients with metastatic disease received chemotherapy. According to the IGCCCG classification for metastatic germ cell tumors, 20 14, 10 and 20 patients were classified as having good, intermediate and poor prognoses, respectively. Half of them were treated with five or more courses of chemotherapy. A total of 21 patients underwent post-chemotherapy RPLND.
Hormone levels
A total of 37 of 50 patients (74%) showed abnormal levels in any of the three tested hormones. The median free T level was 7.0 pg/mL (range 3.4-13.8 pg/mL). A total of 32 patients (64%) showed free T levels <8.5 pg/mL. When the cut-off level of 11.8 pg/mL was used, up to 46 (92%) patients had low free T levels. The median total T level was 4.5 ng/mL (range 2.0-8.5 ng/mL). In contrast to free T, just 13 patients (26%) and four patients (8%) showed total T levels <3.5 ng/mL (12 nmol/L) and <2.3 ng/mL (8 nmol/L), respectively. The median LH level was 8.2 mIU/mL (range 2.4-27.6 mIU/mL). Above normal LH levels were observed in 15 patients (30%). When we evaluated both free T and LH levels, to our surprise, 22 of 32 patients (69%) with a free T level <8.5 pg/mL showed normal LH levels (median 9.7 mIU/mL, range 2.4-27.6 mIU/mL).
All three tested hormone levels in patients were compared with those of the age-matched healthy controls in each 10-year age group (Table 3) . As data of healthy men aged >50 years and TC survivors aged <20 years were lacking, we compared TC patients and healthy men aged between 20 and 49 years. In each age group, the free T levels of patients were significantly lower and LH levels were significantly higher than those of controls. In contrast, total T levels did not differ between patients and controls among men aged 20-29 years and 40-49 years.
Risk factors of low free T and its effect on LOH and ED symptoms
To identify the risk factors for development of free T levels <8.5 pg/mL, clinical variables were examined by univariate and multivariate analysis (Table 4 ). In univariate analysis, patients who were aged ≥44 years at study enrollment had a significantly higher risk of low free T (odds ratio 4.33, P = 0.017). Patients who underwent RPLND also had a significantly higher risk. However, multivariate analysis showed that only age was significantly associated with low free T levels.
The prevalence of patients having LOH and ED symptoms and its association with the presence or absence of hypogonadism determined by each hormonal test is shown in Table 5 . Overall, the prevalence of patients having LOH symptoms at any grade (AMS score of ≥27) was 60%. The prevalence of patients having LOH symptoms was 25%, 62%, 68% and 58% among age groups 20-29 years, 30-39 years, 40-49 years and ≥50 years, respectively. However, its association with hormone levels was rather obscure. The median AMS score of patients with free T levels <8.5 pg/mL did not differ from that of patients with free T levels of ≥8.5 pg/mL. Also, the prevalence of patients having LOH symptoms was not significantly different according to the presence or absence of a low free T or total T level. We further analyzed them according to each subscale, psychological, somatic and sexual domain score. Again, there were no significant differences in each domain score subscale by hormone levels (Table S1 ). The median IIEF-EF score was 12. Overall, 64% of patients were categorized as having moderate or severe ED symptoms. Again, the total IIEF-15 score and IIEF-EF domain score did not differ by free T or total T level. There was no significant association between ED symptoms and free T or total T levels.
Discussion
Hypogonadism and its associated LOH and ED symptoms are major long-term complications of TC survivors.
3-6 Sexual dysfunction in Japanese TC patients was a persisting problem even years after treatment, 6 but limited data are available on the prevalence of hypogonadism, as determined by hormone levels in Japanese TC survivors. In the present study, analysis of free T, total T and LH levels combined with a QoL assessment revealed several important findings.
First, the prevalence of hypogonadism determined by free T level using a cut-off level of 8.5 pg/mL was 64%. A Japanese randomized study showed that ART exerted beneficial effects on the physical and mental status of patients with free T levels <11.8 pg/mL. 21 In the present study, the free T level was below this level in 92% of patients. In contrast, the prevalence of hypogonadism was much lower when determined by total T level. Just 26% and 8% of patients showed total T levels <3.5 ng/mL and 2.3 ng/mL, respectively. These cut-off levels of total T are widely accepted biochemical criteria for LOH in Western countries. 22 The comparison with healthy controls revealed similar findings. As shown in Table 3 , the free T levels of patients were significantly lower than those of controls, but the total T levels of patients were not. This discrepancy can be partly explained by a linear decrease with aging of free T levels but not total T levels in Japanese men. [13] [14] [15] Therefore, it is possible that TC and its treatment might accelerate the age-dependent decrease of free T. As the most important explanation of the acceleration of the decrease of free T, there is a high probability that the serum SHBG level is increased in TC survivors. Unfortunately, we did not evaluate the serum SHBG level. In plasma, testosterone is bound non-specifically to albumin and specifically to SHBG. Unbound free T and testosterone bound to albumin constitute bioavailable testosterone. 23 Therefore, the International Society of Andrology recommends confirmation of LOH by repeating the morning measurement of total T with SHBG to calculate free T in some men for whom total T is near the lower limit. 22 If we had measured SHBG, we could use calculated free T levels for analysis. However, in Japan, measurement of SHBG is not covered by health insurance and is not commonly carried out. To our knowledge, there were just seven published studies that evaluated SHBG and testosterone among TC survivors, 5,9-11,24-26 and only one report included healthy controls. 11 The SHBG levels were not significantly different in TC survivors (median follow up 7 years) and healthy controls. 11 Petersen et al. reported that SHBG levels of TC survivors who received orchiectomy alone were not significantly different between before and after treatment (median follow up 5 months). 26 The other five studies did not include healthy controls or pretreatment levels of SHBG. Two reports stated that SHBG levels were increased after chemotherapy compared with the surveillance group. 24, 25 Three consecutive reports from a single institution Data presented as median, with 25th to 75th percentile in parentheses. †Statistically significant (P < 0.05). stated that SHBG levels did not significantly differ between the chemotherapy group and surveillance group. 5, 9, 10 Therefore, at present, the association of SHBG levels and treatment for TC is not clearly understood.
Second, in the present study, 60% of patients had LOH symptoms at any grade (AMS score of ≥27). When analyzed by age, the prevalence of LOH symptoms in TC patients was 62%, 68% and 50% at 30-39 years, 40-49 years and ≥50 years. Among 2211 healthy Japanese men, the prevalence of LOH symptoms was 43%, 51% and 62-72% in men aged 30-39 years, 40-49 years and ≥50 years. 27 The prevalence of LOH symptoms in TC patients tended to be higher than in healthy Japanese men aged between 30-49 years (68% of TC patients vs 51% of healthy Japanese men), but it was not statistically significant. Depending on the presence or absence of a low free T or total T level in TC patients, the prevalence of LOH symptoms was not significantly different. Horie et al. reported that there was no significant association between testosterone level (free T or total T) and the AMS score (total or subscale). 28 Also, Lackner et al. found no statistically significant correlation between calculated free or total T level and the AMS score in TC survivors. 5 In the present study, the total IIEF-15 score and IIEF-EF domain score also did not differ by free T or total T level.
Third, in the present study, 30% of patients showed abovenormal LH levels. Most of the previous studies also reported a higher LH level in TC patients after treatment, but the proportion of patients with an above-normal LH level ranged from 22% to 55%. 4, 11 This might be due to a difference in reference range between studies. However, in the present study, we made an interesting finding by evaluating both free T and LH levels. In this study, 69% cases of a free T level <8.5 pg/mL and 77% cases of a total T level <3.5 ng/mL showed a normal LH level. These cases could be classified as normogonadotropic hypogonadism (low free or total T with normal LH). This high ratio of normogonadotropic hypogonadism was unexpected. We consider that gonadal damage played a major role in the development of hypogonadism in TC survivors. Therefore, we speculated that primary (hypergonadotropic) hypogonadism is a major form in TC survivors compared with ordinary age-related LOH patients. In a large cross-sectional survey of 3369 men aged 40-79 years, 86% of 438 participants with low total T showed a normal LH level and were classified as having "secondary hypogonadism" (normogonadotropic hypogonadism). 29 The study also showed that "secondary hypogonadism" was associated with obesity, but, in the present study, there was no difference in median BMI between patients with normogonadotropic hypogonadism and hypergonadotropic hypogonadism (24.4 and 25.2, respectively). Also, there was no difference in median age, stage, chemotherapy cycle or AMS score between the two groups. The underlying mechanisms are not clear, but the present results suggest that multiple factors other than gonadal damage might contribute to development of hypogonadism in TC survivors.
To our knowledge, this is the first report regarding the prevalence of hypogonadism determined by free T level in Japanese TC survivors, but there are still three important limitations to the present study. First, the study population was relatively small. Second, we did not evaluate the SHBG level.
Third, we did not analyze the efficacy of ART for TC survivors. At the enrollment in the study, none of the participants had applied for ART, because they did not want it. After receiving the results of this study, we are planning to suggest ART individually to symptomatic TC survivors with low free T levels. Amano et al. reported that four bilateral testicular survivors received ART by the intramuscular injection of testosterone enanthate for >20 months, and their physical and psychological symptoms were relieved. 30 However, in the present study, two cases who underwent bilateral orchiectomy were excluded from analysis.
Despite these limitations, the present data showed a prevalence of hypogonadism as determined by serum free T level in Japanese TC survivors. Because LOH or ED symptoms cannot distinguish hypogonadal patients from eugonadal patients, serum free T measurement is necessary in screening for hypogonadism in TC survivors.
